1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Dermapharm Holding SE

Dermapharm Holding SE

DMPHF
Dermapharm Holding SEUS flagOther OTC
47.69
USD
- -
- -
2.36BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
7.27
7.15
8.9
9.35
10.72
13.02
14.74
17.51
19.03
21.09
21.93
21.64
22.89
Basic EPS, GAAP
- -
- -
0.24
1.54
1.56
1.41
1.43
1.59
3.89
2.49
1.16
2.11
2.46
2.84
Free Cash Flow per Basic Share
- -
0.48
0.47
1.18
0.15
2.49
1.01
1.68
3.51
4.63
3.3
3.03
3.47
4.18
Dividend per Share
- -
0.1
- -
- -
- -
- -
0.77
0.8
0.88
2.17
1.05
0.88
0.9
- -
Book Value per Share
0.66
0.53
0.76
1.06
1.37
4.69
5.18
5.98
9.24
9.87
10.01
11.23
12.9
10.83
Tangible Book Value per Share
-1.14
-1.21
-0.8
-0.56
-1.57
0.15
-4.02
-4.49
-1.16
-0.83
-10.85
-8.99
-6.93
-10.95
Basic Weighted Avg Shares
- -
54
54
50
50
53
54
54
54
54
54
54
54
52
Sales/Revenue/Turnover
- -
391
385
444
467
572
701
794
943
1,025
1,135
1,181
1,165
1,181
Operating Margin (%)
- -
11.3
17.58
19.33
19.44
18.87
17.08
18.3
30.44
23.62
15.86
18.19
19.51
22.41
Depreciation Expense
- -
18
15
14
16
30
48
47
55
95
102
87
92
125
Net Income, GAAP
- -
- -
13
77
78
75
77
86
210
134
62
114
132
147
Effective Tax Rate (%)
- -
6.32
5.28
7.09
11.68
27.83
29.3
31.41
28.7
38.69
42.89
35.04
28.42
24.5
Profit Margin (%)
- -
-0.02
3.3
17.32
16.64
13.16
11.01
10.81
22.23
13.1
5.49
9.64
11.37
12.4
Working Capital
13
72
81
42
112
225
251
267
364
316
236
267
360
318
LT Debt
101
162
151
97
222
233
543
581
575
512
964
890
923
1,030
Total Equity
41
34
44
61
74
256
284
325
500
532
545
608
691
533
Return on Invested Capital (%)
- -
19.88
28.79
35.08
28.38
16.92
11.76
11.09
19.63
12.91
7.11
8.24
9.49
11.83
Return on Capital (%)
- -
4.58
10.55
38.59
30.47
17.95
11.96
10.41
21.53
13.47
7.15
9.57
10.11
11.06
Return on Common Equity (%)
- -
-0.19
36.61
157.1
119.06
46.19
29.07
28.58
51.16
26.09
11.65
19.9
20.39
25.6

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
129
- -
139
LT Borrowings
904
- -
1,013
LT Finance Leases
19
- -
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
50
Market Capitalization
1,813
2,265
2,298

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
703
780
764
Cash, Cash Equivalents & STI
204
254
224
Accounts Receivable, Net
110
136
137
Inventories
325
360
371
Total Current Liabilities
343
390
446
Payables & Accruals
- -
- -
- -
ST Debt
129
- -
139
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.88%
17.61%
13.56%
Free Cash Flow
184.3%
23.81%
14.64%
Net Income, GAAP
67.13%
30.7%
16.37%
Sales/Revenue/Turnover
11.97%
8.18%
-1.34%
Total Cash Common Dividend
- -
18.21%
2.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
299
280
312
291
1,181
2025
302
272
295
296
1,165
2026
306
285
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.81
0.32
- -
- -
2.11
2025
0.62
0.39
- -
- -
2.46
2026
0.84
0.47
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.88
2025
- -
- -
- -
- -
0.9
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hans-Georg Feldmeier
Full Time Employees
3,500
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Lil-Dagover-Ring 7 Grünwald BV Germany 82031
IPO Date
Nov 29, 2022
Website
dermapharm.de
Similar Companies
Indiva Limited (NDVAF)
Invion Limited (IVIXF)
Parenteral Drugs (India) Ltd. (PDPL.NS)
Black Bird Biotech, Inc. (BBBT)
Medcolcanna Organics Inc. (MCCNF)
Acacia Diversified Holdings, Inc. (ACCA)
Business
Dermapharm Holding SE is a Germany-based pharmaceutical company that develops, manufactures, and markets branded generic and over-the-counter (OTC) medicines. The company offers a broad portfolio of more than 600 products across categories including dermatology (e.g., antifungal creams and psoriasis treatments), cough and cold remedies, pain relief medications, vitamins and supplements, ophthalmics, and gastrointestinal drugs; key brands include Mundipharma generics, Linola skincare line, and Verla-Pharm specialties. It operates primarily in Europe, with production facilities in Germany and sales networks in over 20 countries, targeting pharmacies, wholesalers, hospitals, and online retailers. Dermapharm Holding SE was founded in 1997 and is headquartered in Grünwald, near Munich, Germany. [ from previous][ from previous] In recent developments, the company completed the acquisition of Fougera Pharmaceuticals in 2023, significantly expanding its U.S. dermatology presence with topical generics, followed by strategic investments in production capacity at its German sites in 2024 to meet rising demand for OTC products. It announced a partnership with a leading European distributor in early 2025 to enhance market penetration in Eastern Europe and launched new formulations in its Linola brand for sensitive skin conditions. Additionally, Dermapharm reported strong revenue growth in its H1 2025 results, driven by e-commerce expansion and successful tender wins in hospital segments, with no major reorganizations or name changes noted.